Home  /   Products  /   Urology  /   Tamsulosin Canon prolonged action 0.4 mg – [90 capsules]

Tamsulosin Canon prolonged action 0.4 mg – [90 capsules]


A drug used for urinary disorders associated with benign prostatic hyperplasia. Alpha1-blocker

SKU: 62875 Category:


Tamsulosin-Canon Pharmacodynamics
Tamsulosin is a specific blocker of postsynaptic alpha-1-adrenoreceptors located in the smooth muscle of the prostate, bladder neck and prostatic part of the urethra. Blockade of alpha-1-adrenoreceptors by tamsulosin leads to decrease of the tone of the smooth muscles of the prostate, bladder neck and the prostatic part of the urethra and improvement of the outflow of urine. Simultaneously both symptoms of emptying and symptoms of filling, caused by increased tone of smooth muscles and degrusor hyperactivity in benign prostatic hyperplasia (BPH), are reduced.
The ability of tamsulosin to influence on alpha-1-A subtype of adrenoreceptors is 20 times higher than its ability to interact with alpha-1-B subtype of adrenoreceptors, which are located in vascular smooth muscle. Due to its high selectivity, tamsulosin does not cause clinically significant reduction of systemic arterial blood pressure (BP) both in patients with arterial hypertension and in patients with normal baseline BP.


Treatment of dysuric disorders in benign prostatic hyperplasia.


Hypersensitivity to tamsulosin or any other component of the drug; glucose/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption; orthostatic hypotension (including anamnesis); severe hepatic insufficiency; children under 18 years of age.
Severe renal insufficiency (creatinine clearance less than 10 ml/min); arterial hypotension.
Pregnancy and lactation:
The drug Tamsulosin Canon 0.4 mg in capsules is intended for use in males only.


Dosage and administration


  • Adults over 18 years of age as well as elderly patients
  • Orally, after breakfast, with water, take 1 capsule (0.4 mg) once a day. It is not recommended to chew the capsule as this may affect the rate of release of the active substance.
  • In patients with hepatic or renal impairment
  • No dosage regimen adjustment is required in patients with renal impairment and mild to moderate hepatic impairment.